新诺威：关于收购控股子公司石药集团巨石生物制药有限公司部分少数股权交易进展暨完成工商变更登记的公告

Core Viewpoint - The company announced the acquisition of a 29% stake in its subsidiary, Giant Stone Biopharmaceutical Co., Ltd., increasing its ownership from 51% to 80% through a cash transaction valued at 1.1 billion yuan [2]. Group 1 - The board of directors and the supervisory board held meetings on September 30, 2025, to approve the acquisition proposal [2]. - The extraordinary general meeting of shareholders is scheduled for October 16, 2025, to further discuss the transaction [2]. - The transaction has been completed with the necessary registration changes filed with the relevant administrative authority [2].